|
參考文獻 1.Cuan Martinez JR, Mainero Ratchelous FE, Aguilar Gallegos IU, et al. Comparative study of clinical and pathological features of breast cancer in women with 40 years old and younger vs 70 years old and older. Ginecol Obstet Mex 2008; 76: 299-306. 2.Kelsey JL, Horn-Ross PL. Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 1993; 15: 7-16. 3.Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996; 17: 47-67. 4.Anglesio MS, Arnold JM, George J, et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008; 6: 1678-90. 5.Lu C, Dong J, Ma H, et al. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2009; 116: 571-5. 6.Junttila MR, Westermarck J. Mechamisms of MYC stabilization in human malignancies. Cell Cycle. 2008 ;7(5):592-6. 7.Manie E, Vincent-Salomon A, Lehmann-Che J, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009; 69: 663-71. 8.Floyd S, Pines J, Lindon C. APC/C Cdh1 targets aurora kinase to control reorganization of the mitotic spindle at anaphase. Curr Biol 2008; 18: 1649-58. 9.Norris J, Spelic SS, Snyder C, Tinley S. Five families living with hereditary breast and ovarian cancer risk. Clin J Oncol Nurs 2009; 13: 73-80. 10.Hu Z, Li WF, Liu XY, et al. BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases. Zhonghua Yi Xue Za Zhi 2008; 88: 2383-6. 11.Kaas R, Rutgers EJ. Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer. Ned Tijdschr Geneeskd 2008; 152: 2317-8. 12.Niibe Y, Kuranami M, Matsunaga K, Takaya M, Kakita S, Hara T, Sekiguchi K, Watanabe M, Hayakawa K . Value of high-dose radiation therapy for isolated osseous metastasis in breast cancer in terms of oligo-recurrence. Anticancer Res 2008; 28: 3929-31. 13.Spratt JS. Anatomy of the breast. Major Probl Clin Surg 1979; 5: 1-13. 14.Pujol J, Mourou MY, Rabischong P, Lamarque JL. Anatomy of the breast. Soins Gynecol Obstet Pueric Pediatr 1990: 4-6. 15.A Woman''s Guide To Breast Cancer Diagnosis And Treatment" by the California Department of Health Services and "The Breast Buddy Volunteer Training 16.National Cancer Institute 17.American Cancer Association information.--- About Breast cancer 18.Imaginis General Informatio on Breast Cancer 19.Intra M, Gatti G, Luini A, Galimberti V, Veronesi P, Zurrida S, Frasson A, Ciocca M, Orecchia R, Veronesi U. Surgical technique of intraoperative radiotherapy in conservative treatment of limited-stage breast cancer. Arch Surg 2002; 137: 737-40. 20.Bartelink H. Radiotherapy to the conserved breast, chest wall, and regional nodes: is there a standard? Breast 2003; 12: 475-82. 21.Coates AS, Gelber RD, Goldhirsch A. Subsets within the chemotherapy overview. International Breast Cancer Study Group. Lancet 1998; 352: 1783-4. 22.Coates A, Goldhirsch A, Gelber R. Overhauling the breast cancer overview: are subsets subversive? Lancet Oncol 2002; 3: 525-6. 23.Stoltenborg JK, Straney RA, Tritch RJ, Mackin WM, George HJ. Expression and functional characterization of recombinant human vascular cell adhesion molecule-1 (VCAM-1) synthesized by baculovirus-infected insect cells. Protein Expr Purif 1993; 4: 585-93. 24.Cybulsky MI, Fries JW, Williams AJ, Sultan P, Eddy R, Byers M, Shows T, Gimbrone MA Jr, Collins T. Gene structure, chromosomal location, and basis for alternative mRNA splicing of the human VCAM-1 gene. Proc Natl Acad Sci U S A 1991; 88: 7859-63. 25.Lobb RR, Antognetti G, Pepinsky RB, Burkly LC, Leone DR, Whitty A. A direct binding assay for the vascular cell adhesion molecule-1 (VCAM-1) interaction with alpha 4 integrins. Cell Adhes Commun 1995; 3: 385-97. 26.Luscinskas FW, Gimbrone MA, Jr. Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med 1996; 47: 413-21. 27.Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-101. 28.Johnson-Leger C, Aurrand-Lions M, Imhof BA. The parting of the endothelium: miracle, or simply a junctional affair? J Cell Sci 2000; 113 ( Pt 6): 921-33. 29.Shephard RJ, Gannon G, Hay JB, Shek PN. Adhesion molecule expression in acute and chronic exercise. Crit Rev Immunol 2000; 20: 245-66. 30.Vestweber D. Regulation of endothelial cell contacts during leukocyte extravasation. Curr Opin Cell Biol 2002; 14: 587-93. 31.Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996; 88: 3259-87. 32.Komoriya A, Green LJ, Mervic M, Yamada SS, Yamada KM, Humphries MJ. The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J Biol Chem 1991; 266: 15075-9. 33.Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007; 67: 1832-41. 34.Wu TC. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 2007; 67: 6003-6. 35. O''Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C, Given HF. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer. 2002 Nov;38(17):2252-7. 36. F Armenante, M Merola, A Furia, M Tovey and M Palmieri. Interleukin-6 repression is associated with a distinctive chromatin structure of the gene. Nucleic Acids Research 1999;22:4483-4490 37. AM Calcagno, JM Fostel, KKW To, CD Salcido, SE Martin, KJ Chewning, C-P Wu, L Varticovski, SE Bates, NJ Caplen and SV Ambudkar.British Journal of Cancer 2008;98:1515 -1524 38. Natasha Y. Frank, Armen Margaryan, Ying Huang, Tobias Schatton, Ana Maria Waaga-Gasser, Martin Gasser, Mohamed H. Sayegh, Wolfgang Sadee, and Markus H. Frank. ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma. Cancer Res 2005; 65: (10) 39.Ren XQ, Furukawa T, Nakajima Y, Takahashi H, Aoki S, Sumizawa T, Haraguchi M, Kobayashi M, Chijiiwa K, Akiyama S. GSH inhibits trypsinization of the C-terminal half of human MRP1. J Biol Chem 2005; 280: 6231-7. 40.Kang YH, Lee E, Youk HJ, Kim SH, Lee HJ, Park YG, Lim SJ. Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells. Cancer Lett 2005; 217: 181-90. 41.Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ. Doxorubicin in combination with a small TGF-β inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS ONE; 5: e10365.
|